On Thursday, the European Union published its first draft of a Code of Practice for general purpose AI (GPAI) models. The document, which won’t be finalized until May, lays out guidelines for managing risks — and giving companies a blueprint to comply and avoid hefty penalties.

A first draft of a Code of Practice that will apply to providers of general-purpose AI models under the European Union's AI Act has been published,

The European Union has released the first draft of the general-purpose AI code of practice portion of the AI Act. Read for more.

While the new Labour government has ruled out rejoining the EU's single market and customs union, Prime Minister Keir Starmer has said he wants to improve trade ties and diplomatic relations with the bloc. Bailey said Britain needed to look at the wider ...

The UK must rebuild relations following Brexit, the governor of the Bank of England has said, warning of the economic consequences of leaving the European Union. Speaking alongside the chancellor at the annual Mansion House dinner in the City of London,

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug

The European Union's drugs regulator on Thursday recommended approval for Eisai and Biogen's Leqembi in some patients with early Alzheimer's disease, nearly four months after it first rejected the treatment.

The European Union's drugs regulator reversed its decision to block the Alzheimer's drug lecanemab, a treatment aimed at slowing cognitive decline in patients. In July, the Amsterdam-based European Medicines Agency (EMA) denied recommending approval of the drug made by Eisai and Biogen because it considered the risks - especially bleeding and swelling in the brain - to be greater than the potential benefits in a broad population.